Key result
Three months of pitavastatin treatment significantly reduced brachial-ankle pulse wave velocity from 1522 to 1407 cm/s (P < 0.001) in statin-naive patients with hypercholesterolemia.
Why the study?
Although statins improve arterial stiffness, there is limited research on whether pitavastatin, a more recently developed statin, confers similar effects in patients with hypercholesterolemia.
Does pitavastatin reduce arterial stiffness in statin-naive patients with hypercholesterolemia?
Observational (n=115)
Does pitavastatin reduce arterial stiffness in statin-naive patients with hypercholesterolemia?
Absolute Event Rate: 1407% vs 1522%
p-value: p=<0.001
Pitavastatin may reduce arterial stiffness in hypercholesterolemia; leaves open effects on clinical outcomes.
OBJECTIVE: Although several studies have highlighted the benefits of statins in improving arterial stiffness, there is limited research on whether pitavastatin, a more recently developed statin, has similar effects. This study aimed to investigate the impact of pitavastatin on arterial stiffness in patients with hypercholesterolemia. METHODS: This prospective study enrolled 115 patients with hypercholesterolemia (mean age, 59 years; 22% female) who had not previously been treated with statins. Participants underwent lifestyle interventions followed by administration of pitavastatin (2 or 4 mg daily) if target low-density lipoprotein (LDL) cholesterol levels were not achieved. The primary outcome measured was the change in brachial-ankle pulse wave velocity (baPWV) from baseline after three months of treatment. RESULTS: Pitavastatin treatment significantly reduced LDL cholesterol by 41.1% (from 158 ± 28 to 93.0 ± 29.6 mg/dL; P < 0.001). Additionally, systolic blood pressure (SBP) decreased significantly from 130 ± 14 to 126 ± 14 mmHg (P < 0.001), representing a 2.9% reduction, and baPWV decreased significantly from 1522 ± 325 to 1407 ± 289 cm/s (P < 0.001), a 7.6% reduction. There was a significant correlation between changes in SBP and changes in baPWV (r = 0.565; P < 0.001). Even after adjusting for changes in SBP, the reduction in baPWV induced by pitavastatin remained statistically significant (P < 0.001). CONCLUSION: A three-month treatment with pitavastatin effectively reduced arterial stiffness in patients with hypercholesterolemia, alongside significant improvements in lipid profiles and blood pressure reductions. These findings support the use of pitavastatin for managing key cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2024) conducted an observational in Hypercholesterolemia (n=115). Pitavastatin vs. Baseline was evaluated on Change in brachial-ankle pulse wave velocity (baPWV) from baseline after three months of treatment (p=<0.001). Three months of pitavastatin treatment significantly reduced brachial-ankle pulse wave velocity from 1522 to 1407 cm/s (P < 0.001) in statin-naive patients with hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: